Pharsight

Drugs that contain Brexanolone

1. Zulresso patents expiration

ZULRESSO's oppositions filed in EPO
Can you believe ZULRESSO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410077 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US9200088 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US9750822 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US7635773 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US10117951 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US10322139 SAGE THERAP Neuroactive steroid formulations and methods of treating CNS disorders
Jan, 2033

(8 years from now)

US10251894 SAGE THERAP Anticonvulsant activity of steroids
Nov, 2033

(9 years from now)

US10940156 SAGE THERAP Neuroactive steroids, compositions, and uses thereof
Mar, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
New Patient Population (NPP) Jun 16, 2025

NCE-1 date: 2023-06-18

Market Authorisation Date: 17 June, 2019

Treatment: Method of treating postpartum depression

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ZULRESSO family patents

Family Patents